Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] SPIIL is currently in the trading of specialty chemicals and pharma APIs. It has posted inconsistency in its financial performance for the reported periods. The company plans to enter manufacturing activities soon. However, the asking price appears to be greedy based on its financial data so far. The small equity post-IPO indicates longer gestation for migration to the mainboard. There is no harm in skipping this “High Risk/Low Return” bet. Read detail review...
Saroja Pharma Industries India Limited peer comparison with similar listed entities. () (As on March 31, 2023)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | |
|---|---|---|---|---|---|
| EPS Basic | EPS Diluted | ||||
| Saroja Pharma Industries India Limited | 3.61 | 3.61 | 17.33 | 23.27 | 20.85 |
| NGL Fine Chem Limited | 84.57 | 84.57 | 334.35 | 23.15 | 25.29 |
| Sequent Scientific Limited | 0.60 | 0.60 | 41.92 | 223.00 | 1.42 |
1 Based on March 31st, 2023 restated financials statements.
2 Source: Annual Report of Peer Group Companies available on Stock Exchange.
3 Basic & diluted Earnings per share (EPS) is calculated in weighted average number of shares after considering Bonus Issue of Shares.
4 Price Earing (P/E) Ratio in relation to offer Price of ₹ 84/- per shares.
Saroja Pharma IPO Reviews, analysis and views by popular members. Read Saroja Pharma Industries India Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP